.sub-header{display:none;}
Lev Gerlovin, Ezra Josephson | Life Sciences
–>
Lev Gerlovin explores the future of payer response to rising drug prices and discuss strategies that manufacturers may consider to gain a competitive edge in this evolving landscape.
An evidence-based framework to determine funding requirements for NCCPs
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...